Envoy Medical, Inc. · NASDAQ:COCH

Envoy Medical — Investor Presentation (December 2025)

31 slides from Envoy Medical's investor presentation, Dec 16, 2025

  1. Slide 1: Investor Presentation December 2025

    INVESTOR PRESENTATION DECEMBER 2025 www.envoymedical.com NASDAQ: COCH Hear for Life

  2. Slide 2: Forward Looking Statements

    Nasdaq: COCH 2 FORWARD LOOKING STATEMENTS This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward - Looking statements may be identified by the use of words such as “es

  3. Slide 3: C]XʌI. B‚ع›ã‚Õʌ˚ɸɹʒɹBB ʈ ]­‚Ø›ÜIçãÜã‚•¯Â©ʌɸɾʒɿBB ʈ dtʌ ɹʒɶBB ʈ ʈB‚ع›ã‚ã‚‚ÜȨ››ÁŽ›Øɶɷʍɸɶɸɻ

    C]XʌI. B‚ع›ã‚Õʌ˚ɸɹʒɹBB ʈ ]­‚Ø›ÜIçãÜã‚•¯Â©ʌɸɾʒɿBB ʈ dtʌ ɹʒɶBB ʈ ʈB‚ع›ã‚ã‚‚ÜȨ››ÁŽ›Øɶɷʍɸɶɸɻ

  4. Slide 4: Investment Highlights

    Nasdaq: COCH 4 INVESTMENT HIGHLIGHTS x Hearing health company positioned to transform the multi - billion - dollar cochlear implant (CI) market with the first fully - implanted cochlear implant x Acclaim ® CI candidate in late - stage development: Pivotal trial enrollment anticipated to complete in

  5. Slide 5: Significant Market Opportunity

    Nasdaq: COCH 5 SIGNIFICANT MARKET OPPORTUNITY □ An estimated ~2.8M U.S. adults are candidates for cochlear implants 1 □ Only about 5% of adults who could benefit from a CI have have gotten one 2 □ 95% of the adult CI market remains untapped. □ If approved, Acclaim ® CI pricing is anticipated to be ~

  6. Slide 6: Large & Growing Need

    Nasdaq: COCH 6 LARGE & GROWING NEED • 14% of all Americans have clinically - relevant hearing loss with it becoming more common with age – nearly one - fourth of Americans over the age of sixty and two - thirds of Americans over the age of seventy. 1 • Hearing loss is the third most common chronic p

  7. Slide 7: Envoy's Market Position by Levels of Hearing Loss

    Nasdaq: COCH Acclaim ® CI Hearing Aids Esteem ® 7 LEVELS OF HEARING LOSS Envoy’s Market Position

  8. Slide 8: Traditional Cochlear Implants

    Nasdaq: COCH 8 TRADITIONAL COCHLEAR IMPLANTS For illustrative purposes only. Experience and results may vary. Sound processor (External) • Picks up sound through off - ear or behind - the - ear microphone(s) • Processes sound into digital information • Contains battery • Does not use natural hearing

  9. Slide 9: External Components Have Drawbacks

    Nasdaq: COCH 9 EXTERNAL COMPONENTS HAVE DRAWBACKS • Visible Hardware: Noticeable and unsightly display of the wearer’s disability; stigma • Bedtime Removal: External devices are taken off at night leaving the user without hearing • Removal Before Showering/Activities: External devices can be damaged

  10. Slide 10: Fully Implanted Acclaim Cochlear Implant

    Nasdaq: COCH 10 FULLY IMPLANTED ACCLAIM ® COCHLEAR IMPLANT CAUTION — Investigational device. Limited by Federal (or United States) law to investigational use • Developed to be the first of - its - kind fully implanted cochlear implant • Breakthrough Device Designation (FDA 2019) • Designed to addres

  11. Slide 11: Fully Implanted Acclaim Cochlear Implant (Video)

    Nasdaq: COCH 11 FULLY IMPLANTED ACCLAIM ® COCHLEAR IMPLANT VIDEO TIP : Hover cursor over box for play button to appear under box.

  12. Slide 12: First-of-its-Kind Fully Implanted Cochlear Implant

    Nasdaq: COCH 12 FIRST - OF - ITS - KIND FULLY IMPLANTED COCHLEAR IMPLANT DISCREET • No need for externally worn components • Designed to use the ear to pick up sound DEPENDABLE • Designed to allow 24/7 hearing • For use in many environments and activities EASE OF USE • No expensive external sound pr

  13. Slide 13: Acclaim CI Leverages Sensor from Envoy's First FDA-Approved Implant

    Nasdaq: COCH 13 ACCLAIM ® CI LEVERAGES SENSOR FROM ENVOY’S FIRST FDA - APPOVED IMPLANT • Envoy’s Esteem ® implant received FDA approval from the U.S. Food and Drug Administration in 2010. It was the first, and remains the only, fully implanted active hearing device to successfully receive FDA approv

  14. Slide 14: The Race to Fully Implanted CIs

    Nasdaq: COCH 14 THE RACE TO FULLY IMPLANTED CIs X • • • Feasibility Study on Record X x x • Breakthrough Device Designation from U.S. FDA for Fully Implanted Cochlear Implant X ? ? • Investigational Device Exemption (IDE) application approved by FDA to begin Pivotal Clinical Trial in US. x ? ? • Enr

  15. Slide 15: Durable Differentiation

    Nasdaq: COCH 15 DURABLE DIFFERENTIATION Envoy Medical believes it has a superior design that will offer significant advantages over the competitive landscape • Cochlear and Med - El have both publicly stated that they are in early studies with their versions of “totally implantable” cochlear implant

  16. Slide 16: Important Design Differences

    Nasdaq: COCH 16 IMPORTANT DESIGN DIFFERENCES • Cochlear and Med - El use sub - cutaneous microphones. • Envoy Medical uses a piezoelectric middle ear sensor. • Cochlear and Med - El have microphones behind the ear. • Envoy Medical picks up sound through the ear’s natural pathway. • Envoy Medical all

  17. Slide 17: Concentrated & Mature Competitive Landscape

    Nasdaq: COCH 17 CONCENTRATED & MATURE COMPETITIVE LANDCAPE Market Share: ≈65% (ASX: COH) $1.52B Revenue ~$11.59B Market Cap 1 Market Share: ≈15% Privately Held Market Share: ≈10% (SWX: SOON) $4.36B Revenue ~$19.1B Market Cap NOTE: 1. PitchBook Data, as of May 2025; Market share data shown are estima

  18. Slide 18: Acclaim Cochlear Implant Pivotal Trial

    Nasdaq: COCH 18 ACCLAIM ® COCHLEAR IMPLANT PIVOTAL TRIAL Pivotal Clinical Trial Evaluating Safety & Efficacy of the Fully Implanted Acclaim® Cochlear Implant (CI) ClinicalTrials.gov ID# NCT06699797 Trial Objective: Ability to safely and effectively treat severe to profound sensorineural hearing loss

  19. Slide 19: Acclaim CI Pivotal Trial Sites

    Nasdaq: COCH 19 ACCLAIM ® CI PIVOTAL TRIAL SITES • The 7 sites in the Pivotal trial are expected to serve as the backbone of the commercial launch • Mayo Clinic, Rochester, MN • Cleveland Clinic, Cleveland, OH • Community Hospital/Hearts for Hearing, Oklahoma City, OK • University of Florida, Gaines

  20. Slide 20: Anticipated Timeline to Commercialization

    Nasdaq: COCH 20 ANTICIPATED TIMELINE TO COMMERCIALIZATION 2019 2022 2023 2027 2027 FDA Breakthrough Device Designation Q3 2022 FDA Granted Early Feasibility Study IDE Q4 2022 Full EFS Enrollment 3 patients at Mayo Clinic (Rochester, MN) Q2 2023 Colin Driscoll, MD ACIA Presentation Q4 2024 FDA Grante

  21. Slide 21: Target Sites for Implantation at Launch

    Nasdaq: COCH 21 TARGET SITES FOR IMPLANTATION AT LAUNCH 35 target launch sites include: • ACCLAIM CI ® pivotal trial sites • Envoy’s Cochlear Implant Advisory Board (CIAB) Member sites • Current ESTEEM ® implant sites • New sites that have indicated high interest in ACCLAIM CI ® These 35 sites accou

  22. Slide 22: Commercial Opportunity

    Nasdaq: COCH 22 COMMERCIAL OPPORTUNITY Reimbursement pathway for cochlear implants already exists • Exempt from Medicare’s “hearing aid exclusion” • Positive National Coverage Determination (NCD) 50.3 already exists for cochlear implants • Many private payors also cover cochlear implants for those w

  23. Slide 23: Executive Leadership Team

    Nasdaq: COCH 23 EXECUTIVE LEADERSHIP TEAM Brent T. Lucas, CEO Brent Lucas has been the Chief Executive Officer of Envoy Medical Corporation for the last ten years and brings over 18 years of experience with active implantable hearing devices. He is currently one of the longest serving CEOs of any co

  24. Slide 24: Cochlear Implant Advisory Board

    Nasdaq: COCH Jannine “Jan” Larky , M.A. ǀ Stanford Ear Institute (Palo Alto, CA) Dr. Aniket Saoji , Ph.D. ǀ Mayo Clinical (Rochester, MN) Melissa Hall , Au.D . ǀ University of Florida (Gainesville, FL) Dr. Camille Dunn , Ph.D. ǀ University of Iowa (Iowa City, IA) Sara Neummann , Au.D . ǀ Hearts for

  25. Slide 25: Anticipated Milestones & Corporate Priorities

    Nasdaq: COCH 25 ANTICIPATED MILESTONES & CORPORATE PRIORITIES ‡ ƬƬǼƏǣȅ Š  !X  ¨ǣɮȒɎƏǼ  ÁȸǣƏǼ  0ȇȸȒǼǼȅƺȇɎ  ‡ RƏǼǔɯƏɵ  ȵȒǣȇɎ  Ȓȇ  ƺȇȸȒǼǼȅƺȇɎ  ٫  ȅǣƳٖǼƏɎƺ  (ƺƬƺȅƫƺȸ ‡ 0ȇȸȒǼǼȅƺȇɎ  ƬȒȅȵǼƺɎǣȒȇ  ٢ƏǼǼ  ȵƏɎǣƺȇɎɀ  ǣȅȵǼƏȇɎƺƳ٣  ٫  ȅǣƳ ٮ ª ׏  א׎אה ‡ XȅȵǼƏȇɎ  ƏƬɎǣɮƏɎƺƳ  ǔȒȸ  ƏǼǼ  דה  ɎȸǣƏǼ

  26. Slide 26: Contact Details

    Contact Details www.envoymedical.com/investors Investor Relations 651 - 361 - 8043 InvestorRelations@EnvoyMedical.com For Media Inquiries: Media@EnvoyMedical.com Phil Carlson KCSA Strategic Communications 212 - 896 - 1233 Envoy@kcsa.com

  27. Slide 27: he aaas

    7 he aaas _ : _~ Y; a

  28. Slide 28: Board of Directors

    Nasdaq: COCH ENVOY MEDICAL, INC. Board of Directors hƏȇǣɀ³ȅǣɎǝ ٮ JȒȅƺɿ XȇƳƺȵƺȇƳƺȇɎ(ǣȸƺƬɎȒȸً zȒȅJȒɮ  !ȒȅȅǣɎɎƺƺ !ǝƏǣȸ ‡ …ɮƺȸ ב׎ ɵƺƏȸɀȒǔƺɴƺƬɖɎǣɮƺ ƺɴȵƺȸǣƺȇƬƺƏɎhȒǝȇɀȒȇۭ hȒǝȇɀȒȇًxƏȸɀًkȸƏǔɎƏȇƳ¨ƺȵɀǣ!Ȓِ ‡ xȒɀɎȸƺƬƺȇɎȸȒǼƺɯǣɎǝhۭhًhƏȇǣɀ ǼƺƳɎǝƺƫȸƏȇƳǣƳƺȇɎǣɎɵƺǔǔȒȸɎɀɎȒ ƺɮȒǼɮƺɎǝƺڟ או 

  29. Slide 29: Traditional Cochlear Implants Bypass Natural Ear Structures

    kåƊĈåƁ͚΅tI 29 TRADITIONAL COCHLEAR IMPLANTS BYPASS NATURAL EAR STRUCTURES Sound waves travel down the ear canal and hit the eardrum Sound waves are transmitted mechanically through the ossicular chain to the cochlea The cochlea converts sound waves to electrical signals which travel to the brain v

  30. Slide 30: Envoy's Rechargeable Battery Expected to Last Several Days Between Charges

    Nasdaq: COCH 30 ENVOY’S RECHARGEABLE BATTERY EXPECTED TO LAST SEVERAL DAYS BETWEEN CHARGES Remain mobile while charging with the charging system Battery charging system only worn while charging, a few hours every 4+ days** 0ȇɮȒɵ ټ ɀ ƫƏɎɎƺȸɵǣɀ ɀǣȅǣǼƏȸɎȒȒɎǝƺȸ ȅƺƳǣƬƏǼƳƺɮǣƬƺɀ ɯǣɎǝǣȅȵǼƏȇɎƺƳً ȸƺƬ

  31. Slide 31: Hearing Loss: Global Market

    Nasdaq: COCH 31 HEARING LOSS: GLOBAL MARKET Key Facts from the World Health Organization 1 : • More than 1.5 billion people may have some form of hearing loss during their lifetime. • Approximately 430 million individuals have “disabling hearing loss” that requires intervention. 2 • By 2050, these n

Envoy Medical — Investor Presentation (December 2025) on 6ix